

TGA approves Telezon's SoloFlow

18 October 2013 | News | By BioSpectrum Bureau



Singapore: Telezon's flagship SoloFlow Reconstitution Needle (polymer needle) has been accepted by Therapeutic Goods Australia (TGA) and is now approved to be sold in the Australian market.

In the last two years, SoloFlow was granted the CE Mark for Europe and FDA registration for the US.

Telezon is currently pursuing capital investment to expand the business and accelerate market entry for its other world-patented polymer products and technologies including the Blunt SoloFlow; DuoDraw; and PolyDermic solutions.